HPS Pharmacies wish to advise that A. Menarini Australia have given notice of a shortage of:
This shortage is due to inconsistent supply from the overseas manufacturer. A. Menarini Australia have struggled to maintain supply for some time and are no longer able to fulfil orders; and cannot offer a date when supplies will return to normal. They are in consultation with the TGA and will forward more information when it becomes available.
No other brands of benztropine mesylate 2mg injection are registered in Australia, however HPS Pharmacies have sourced an alternative product that may only be supplied to patients under the Special Access Scheme.
HPS Pharmacies can offer immediate supply to Category A, seriously ill patients, pending completion and forwarding of the Category A SAS form by the medical practitioner. The form for Category B patients, and TGA approval, must be completed prior to supply to these patients. Supplies via the Special Access Scheme are not subsidised by the PBS.
There are no difficulties in supply of the oral medicine Benztrop (benztopine mesylate) 2 mg tablet, 60.
HPS Pharmacies will continue to notify of changes in availability as we become aware. Please retain this notice in a prominent position, including other related business units as a reminder for all staff members until supply returns to normal.
Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please do not hesitate to contact your pharmacist at HPS Pharmacies or A. Menarini Australia Customer Service on 02 9080 7200.
Information regarding expected dates for supply may vary subject to delays which are out of our control. HPS Pharmacies does not accept responsibility for such changes but will endeavour to keep our clients updated as information is made available from drug manufacturers or wholesalers.